Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Executive Changes (Oct 6, 2025)

Reports
Leadership Changes
Filing Date
Filed October 6, 2025
Period End
October 1, 2025
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Material agreement8-K · Aug ’22Aug ’22
  4. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 8-K filed October 6, 2025. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. filed this Current Report on Form 8-K under Item 5.02, reporting executive leadership changes.

On October 1, 2025, Cortney Caudill was appointed Senior Vice President, Chief Operating Officer, effective immediately. She had already served as the Company's Senior Vice President, Chief Operations Officer since October 2023, so the change is a promotion within the existing executive team rather than an external hire. The filing sets out Ms. Caudill's compensation in her new role.

Her initial annual base salary as Chief Operating Officer is $600,000,a and she is eligible to participate in the Company's executive officer incentive plans with a 2025 bonus target equal to 50% of base salary. She will also receive an equity award valued at $500,000 in connection with the appointment, split 50% stock options and 50% restricted stock units, vesting under the Company's standard four-year schedule. She will be eligible for long-term incentive awards under the Compensation Committee's practices for executive officers.

The filing states that Ms. Caudill has no family relationships with any director or executive officer and no direct or indirect material interest in any transaction in which the Company is a participant. Her prior experience includes Aeglea Biotherapeutics, where she most recently served as Chief Product Officer, and several life sciences operational roles from 2002 to 2018.

Key Highlights

  1. Cortney Caudill appointed Senior Vice President, Chief Operating Officer effective October 1, 2025 (appointment date stated in the filing as October 1, 2025, effective immediately)
  2. Ms. Caudill previously served as Senior Vice President, Chief Operations Officer since October 2023, so this is an internal promotion
  3. Initial annual base salary set at $600,000 as Chief Operating Officer
  4. 2025 bonus target equal to 50% of base salary, with eligibility under the executive officer incentive plans
  5. Equity award valued at $500,000, delivered 50% in stock options and 50% in restricted stock units, vesting over a standard four-year schedule
  6. Filing states no family relationships with directors or executive officers and no material related-party interest
  7. Prior experience includes Aeglea Biotherapeutics (2019 to October 2023, most recently Chief Product Officer) and operational roles at several life sciences companies from 2002 to 2018

Frequently Asked Questions

  1. Who was appointed to a new role at Halozyme in this filing?

    Cortney Caudill, who was appointed Senior Vice President, Chief Operating Officer, effective immediately as of October 1, 2025. She had previously held the role of Senior Vice President, Chief Operations Officer since October 2023.

  2. What compensation will the new Chief Operating Officer receive?

    Her initial annual base salary is $600,000. She is eligible for the executive officer incentive plans with a 2025 bonus target equal to 50% of her base salary, and she will receive an equity award valued at $500,000, split 50% stock options and 50% restricted stock units, vesting under the Company's standard four-year schedule.

  3. Does the appointment involve any related-party or family relationships?

    The filing states that Ms. Caudill has no family relationships with any director, executive officer, or person nominated to become one, and that she has no direct or indirect material interest in any transaction or arrangement in which the Company is a participant.

  4. What is Ms. Caudill's professional background?

    The filing says she served at Aeglea Biotherapeutics from 2019 to October 2023 in roles including Vice President of Manufacturing, Senior Vice President of Technical Operations, and most recently Chief Product Officer. From 2002 to 2018 she held operational roles at companies including Cambrex Bioscience, Vaxagen, Genentech, Vetter Pharma International, Samsung Biologics, Baxalta, and Eaulife NA. She holds a B.S. in biology and a B.A. in psychology from the University of Texas.